Study 27 of 29Semaglutide literatureThe lancet. Diabetes & endocrinologyTop journal2026
1-year outcomes of semaglutide, tirzepatide, and sleeve gastrectomy in obesity in type 2 diabetes: a retrospective cohort study.
Not reported in abstract.
Where it sits
this study against the rest of the semaglutide corpus7
Preclinical · this one
16
Observational
0
Open-label
2
Randomised
4
Reviews
Summary and findings
Not reported in abstract.
How much of this paper we could read: title only (0.00). The feed gave us little more than the title, so our summary is thin. This says nothing about the study's quality — read the source. What this means →
2026
Background
Not reported in abstract.
Methods
Not reported in abstract.
Results
Not reported in abstract.
Interpretation
Not reported in abstract.
Limitations
Not reported in abstract.
Elsewhere in the Semaglutide corpus
DCagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study.The lancet. Diabetes & endocrinology · 2026—DEfficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study.The lancet. Diabetes & endocrinology · 2026—BComparison of lifestyle, surgery, and semaglutide for weight management in endometrial cancer: a prospective observational study.Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology · 2026 · sleeve gastrectomy group had a BMI reduction difference of 4.04 kg/m² compared to the semaglutide group, p < 0.05HumanBGLP-1 and GIP receptor agonism does not directly drive skeletal muscle atrophy or impair myogenesis in primary human myotubesbiorxiv-preprint · 2026 · Semaglutide reduced glycolytic and total ATP production rates, exact values not reported.HumanBReal-World Study of Cardiac Remodeling on Semaglutide and Tirzepatide Therapy Using Longitudinal Echocardiographybiorxiv-preprint · 2026 · LV mass decreased from 198.4 ± 69.6 g to 176.6 ± 66.0 g in super-responders, p < 0.001.HumanBExenatide Is Associated with Superior Gastrointestinal Motility Slowing Among GLP-1 Receptor Agonistsbiorxiv-preprint · 2020 · n=20 · Prevalence of anti-constipation prescriptions increased from 11.09% to 18.62% in the exenatide cohort over 12 months, p=6.75×10⁻⁴.Human